Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Merck
Baxter
Medtronic

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Lupin Atlantis Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for LUPIN ATLANTIS, and when can generic versions of LUPIN ATLANTIS drugs launch?

LUPIN ATLANTIS has fourteen approved drugs.

There are four US patents protecting LUPIN ATLANTIS drugs. There is one tentative approval on LUPIN ATLANTIS drugs.

There are eighty-four patent family members on LUPIN ATLANTIS drugs in thirty-eight countries and sixteen supplementary protection certificates in nine countries.

Summary for Lupin Atlantis
International Patents:84
US Patents:4
Tradenames:9
Ingredients:8
NDAs:14
Patent Litigation for Lupin Atlantis: See patent lawsuits for Lupin Atlantis

Drugs and US Patents for Lupin Atlantis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Atlantis LEVOTHYROXINE SODIUM levothyroxine sodium TABLET;ORAL 209713-005 Jan 18, 2019 AB1,AB2,AB3 RX No No   Start Trial   Start Trial
Lupin Atlantis DESOXIMETASONE desoximetasone SPRAY;TOPICAL 208124-001 Mar 16, 2018 AT RX No No   Start Trial   Start Trial
Lupin Atlantis DESOXIMETASONE desoximetasone OINTMENT;TOPICAL 208044-001 Dec 12, 2016 AB RX No No   Start Trial   Start Trial
Lupin Atlantis DESOXIMETASONE desoximetasone OINTMENT;TOPICAL 208104-001 Dec 1, 2016 AB RX No No   Start Trial   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 AB RX Yes Yes 7,101,574   Start Trial Y Y   Start Trial
Lupin Atlantis TRIAMCINOLONE ACETONIDE triamcinolone acetonide CREAM;TOPICAL 208763-001 Feb 1, 2017 AT RX No No   Start Trial   Start Trial
Lupin Atlantis OSELTAMIVIR PHOSPHATE oseltamivir phosphate CAPSULE;ORAL 208348-001 Jan 9, 2018 AB RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Lupin Atlantis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 4,800,079   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 4,800,079   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-002 Nov 30, 2004 4,800,079   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LUPIN ATLANTIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14

Supplementary Protection Certificates for Lupin Atlantis Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1214076 SZ 49/2008 Austria   Start Trial PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
1214076 49/2008 Austria   Start Trial PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
0398460 C300221 Netherlands   Start Trial PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1214076 C01214076/01 Switzerland   Start Trial PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
0136011 2000C/027 Belgium   Start Trial PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1380301 2009C/007 Belgium   Start Trial PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811
0771217 CA 2006 00038 Denmark   Start Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Harvard Business School
Colorcon
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.